DK0432040T3 - Heterocykliske acylaminothiazolderivater, deres fremstilling samt farmaceutiske midler indeholdende dem - Google Patents

Heterocykliske acylaminothiazolderivater, deres fremstilling samt farmaceutiske midler indeholdende dem

Info

Publication number
DK0432040T3
DK0432040T3 DK90403458.4T DK90403458T DK0432040T3 DK 0432040 T3 DK0432040 T3 DK 0432040T3 DK 90403458 T DK90403458 T DK 90403458T DK 0432040 T3 DK0432040 T3 DK 0432040T3
Authority
DK
Denmark
Prior art keywords
heterocyclic
preparation
pharmaceutical agents
agents containing
acylaminothiazole derivatives
Prior art date
Application number
DK90403458.4T
Other languages
Danish (da)
English (en)
Inventor
Jean-Pierre Bras
Daniel Frehel
Danielle Gully
Gerard Valette
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26227714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0432040(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR8916122A external-priority patent/FR2655344B1/fr
Priority claimed from FR9005669A external-priority patent/FR2661677B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK0432040T3 publication Critical patent/DK0432040T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
DK90403458.4T 1989-12-06 1990-12-05 Heterocykliske acylaminothiazolderivater, deres fremstilling samt farmaceutiske midler indeholdende dem DK0432040T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8916122A FR2655344B1 (fr) 1989-12-06 1989-12-06 Derives heterocycliques d'acylaminothiazoles, leur preparation et compositions pharmaceutiques en contenant.
FR9005669A FR2661677B1 (fr) 1990-05-04 1990-05-04 Derives heterocycliques d'acylaminothiazoles, leur preparation et compositions pharmaceutiques en contenant.

Publications (1)

Publication Number Publication Date
DK0432040T3 true DK0432040T3 (da) 1994-10-31

Family

ID=26227714

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90403458.4T DK0432040T3 (da) 1989-12-06 1990-12-05 Heterocykliske acylaminothiazolderivater, deres fremstilling samt farmaceutiske midler indeholdende dem

Country Status (20)

Country Link
US (2) US5189049A (de)
EP (1) EP0432040B2 (de)
JP (2) JP2760903B2 (de)
KR (1) KR0147281B1 (de)
AR (1) AR248138A1 (de)
AT (1) ATE109145T1 (de)
AU (1) AU628696B2 (de)
CA (1) CA2031463C (de)
DE (1) DE69011059T3 (de)
DK (1) DK0432040T3 (de)
ES (1) ES2057490T5 (de)
FI (1) FI94249C (de)
GR (1) GR3025940T3 (de)
HK (1) HK1002030A1 (de)
HU (2) HU218276B (de)
IE (1) IE68593B1 (de)
IL (1) IL96577A (de)
LV (1) LV5802B4 (de)
MX (1) MX9203027A (de)
NO (1) NO179584C (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
FR2701708B1 (fr) * 1993-02-19 1995-05-19 Sanofi Elf Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
FR2703995B1 (fr) * 1993-04-16 1995-07-21 Sanofi Elf 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant.
FR2714059B1 (fr) * 1993-12-21 1996-03-08 Sanofi Elf Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2768737B1 (fr) * 1997-09-19 2000-05-19 Sanofi Sa Derives de carboxamidothiazoles, leur preparation, les compositions pharmaceutiques en contenant
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
NZ503788A (en) 1997-10-27 2002-11-26 Agouron Pharma 4-aminothiazole derivatives and their use as inhibitors of cyclin-dependent kinases
FR2781227B1 (fr) * 1998-07-20 2002-02-22 Sanofi Sa Procede pour la preparation du sel potassique du lintitript
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
DE19908537A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908538A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
EP1816127A1 (de) 1999-04-22 2007-08-08 H. Lundbeck A/S Triazin-derivate zur verwendung als selektive npy(y5)-antagonisten
US6989379B1 (en) 1999-04-22 2006-01-24 H. Lundbick A/S Selective NPY (Y5) antagonists
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
US6225330B1 (en) 1999-06-30 2001-05-01 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US6214853B1 (en) 1999-06-30 2001-04-10 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US6222040B1 (en) 1999-06-30 2001-04-24 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
WO2001058869A2 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US7732484B2 (en) * 2000-08-01 2010-06-08 University Of Virginia Patent Foundation Use of selective adenosine A1 receptor allosteric enhancers to manipulate angiogenesis
IL156828A0 (en) * 2001-01-12 2004-02-08 Waratah Pharmaceuticals Inc Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
WO2002059099A1 (en) * 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Cyclic compounds having thrombopoietin receptor agonism
JPWO2002062775A1 (ja) * 2001-02-02 2004-06-10 山之内製薬株式会社 ２−アシルアミノチアゾール誘導体又はその塩
EP1314733A1 (de) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indol-2-carbonsäureamide als Faktor-Xa-Hemmer
JP2005529846A (ja) * 2002-01-16 2005-10-06 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ１アデノシン受容体の２−アミノチアゾールアロステリックエンハンサ
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
DK1466912T3 (da) 2002-01-18 2013-07-01 Astellas Pharma Inc 2-acylaminothiazolderivat eller salt deraf
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
CA2494134A1 (en) * 2002-05-24 2003-12-04 Waratah Pharmaceuticals, Inc. Treatment for diabetes
EP1837031B1 (de) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methoden und Kompositionen um Diabetes zu behandeln
BR0312023A (pt) 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
US20080039379A1 (en) * 2003-05-27 2008-02-14 Waratah Pharmaceuticals, Inc. Compositions Comprising Gastrin Compounds and Their Use in Diabetes
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
EP1532980A1 (de) * 2003-11-24 2005-05-25 Novo Nordisk A/S N-Heteroaryl Indol-Carboxamide und deren analoga zur Vewendung als glucokinase Aktivatoren zur Behandlung von Diabetes
CA2551611C (en) 2003-12-26 2013-06-25 Kyowa Kirin Co., Ltd. Thiazole derivatives for treating or preventing parkinson's disease
JP4834840B2 (ja) 2004-01-06 2011-12-14 ノヴォ ノルディスク アー／エス ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
CA2575339A1 (en) * 2004-08-05 2006-02-09 F. Hoffmann-La Roche Ag Substituted n-acyl-2-aminothiazoles
SG155222A1 (en) * 2004-08-13 2009-09-30 Genentech Inc Thiazole based inhibitors of atp-utilizing enzymes
WO2006080406A1 (ja) * 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. 三環性化合物
WO2006084033A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006137527A1 (ja) 2005-06-23 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. チアゾール誘導体
ES2382815T3 (es) 2005-07-08 2012-06-13 Novo Nordisk A/S Dicicloalquilcarbamoil ureas como activadores de glucoquinasa
US7884210B2 (en) 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
CA2628848A1 (en) * 2005-11-08 2007-05-18 Astellas Pharma Inc. Compositions and methods for treating thrombocytopenia
BRPI0619730A2 (pt) * 2005-12-12 2011-10-11 Genelabs Tech Inc compostos antivirais de n-(anel aromático de 5 membros)-amido
CN101096363B (zh) * 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途
EP2452674B1 (de) * 2006-08-08 2014-03-26 Akarx, Inc. Zusammensetzungen und Verfahren zur Erhöhung der Blutplättchenanteile bei Menschen
WO2008084043A1 (en) 2007-01-09 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
WO2008084044A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Urea glucokinase activators
JP5607025B2 (ja) 2008-04-21 2014-10-15 シグナム バイオサイエンシーズ， インコーポレイテッド 化合物、組成物およびそれらを作製する方法
EP2464352A1 (de) * 2009-08-14 2012-06-20 Eisai Inc. Verwendung von e5501 zur anregung der thrombozytenproduktion
DE102011083271A1 (de) * 2011-09-23 2013-03-28 Beiersdorf Ag Aromatische Amidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Aromatischen Amidothiazolen
AU2014275643B2 (en) * 2013-06-05 2018-08-09 C&C Research Laboratories Heterocyclic derivatives and use thereof
US9914740B2 (en) 2013-07-02 2018-03-13 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
EP3016950B1 (de) 2013-07-02 2017-06-07 Bristol-Myers Squibb Company Tricyclische pyrido-carboxamid-derivate als rock inhibitoren
CN109111427B (zh) * 2017-06-22 2023-06-02 中国科学院广州生物医药与健康研究院 一种吲哚类化合物及其应用
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CA3181722A1 (en) 2020-06-08 2021-12-16 Jing TENG Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340092A2 (fr) * 1976-02-09 1977-09-02 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
AT367871B (de) * 1980-05-16 1982-08-10 Hoerbiger Ventilwerke Ag Anordnung zur selbsttaetigen druckentlastung von verdichtern
FR2482596A1 (fr) * 1980-05-19 1981-11-20 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament
JPS5978171A (ja) * 1982-10-26 1984-05-04 Ikeda Mohandou:Kk 複素環式化合物
FR2566405B1 (fr) * 1984-06-25 1986-09-26 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2 par une fonction aminee, leur preparation, leur application comme medicaments, les compositions les renfermant et les intermediaires nouveaux obtenus
EP0208510B1 (de) * 1985-07-09 1991-09-11 Pfizer Inc. Substituierte Oxindol-3-carboxamine als entzündungshemmendes und schmerzstillendes Mittel
DE3705934A1 (de) * 1987-02-25 1988-09-08 Nattermann A & Cie Indolyl-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4971978A (en) * 1987-09-21 1990-11-20 Nadzan Alex M Derivatives of D-glutamic acid and D-aspartic acid
WO1989005812A1 (fr) * 1987-12-22 1989-06-29 Yoshitomi Pharmaceutical Industries, Ltd. Composes de thienodiazepine et leur utilisation en medecine
GB8804448D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
GB8820231D0 (en) * 1988-08-25 1988-09-28 Fujisawa Pharmaceutical Co New benzazole compounds processes for preparation thereof & pharmaceutical composition comprising same
FR2701708B1 (fr) * 1993-02-19 1995-05-19 Sanofi Elf Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
FR2703995B1 (fr) * 1993-04-16 1995-07-21 Sanofi Elf 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
MX9203027A (es) 1992-07-01
IE68593B1 (en) 1996-06-26
HUT59400A (en) 1992-05-28
AU6777990A (en) 1991-06-20
JP2760903B2 (ja) 1998-06-04
DE69011059T3 (de) 1998-04-09
GR3025940T3 (en) 1998-04-30
EP0432040B2 (de) 1997-12-17
JPH10130147A (ja) 1998-05-19
AR248138A1 (es) 1995-06-30
AU628696B2 (en) 1992-09-17
IL96577A0 (en) 1991-09-16
CA2031463A1 (en) 1991-06-07
LV5802B4 (lv) 1997-08-20
HU211866A9 (en) 1995-12-28
EP0432040B1 (de) 1994-07-27
FI94249C (fi) 1995-08-10
USRE37094E1 (en) 2001-03-13
EP0432040A1 (de) 1991-06-12
DE69011059D1 (de) 1994-09-01
HU218276B (en) 2000-07-28
CA2031463C (en) 2000-07-25
FI905941A0 (fi) 1990-12-03
IL96577A (en) 1994-06-24
HU908075D0 (en) 1991-06-28
FI905941A7 (fi) 1991-06-07
DE69011059T2 (de) 1995-03-02
KR0147281B1 (ko) 1998-08-17
US5189049A (en) 1993-02-23
NO905255L (no) 1991-06-07
KR910011814A (ko) 1991-08-07
LV5802A4 (lv) 1997-02-20
ES2057490T3 (es) 1994-10-16
NO905255D0 (no) 1990-12-05
ATE109145T1 (de) 1994-08-15
ES2057490T5 (es) 1998-03-16
FI94249B (fi) 1995-04-28
NO179584C (no) 1996-11-06
JPH03279374A (ja) 1991-12-10
NO179584B (no) 1996-07-29
IE904310A1 (en) 1991-06-19
JP3035253B2 (ja) 2000-04-24
HK1002030A1 (en) 1998-07-24

Similar Documents

Publication Publication Date Title
DK0432040T3 (da) Heterocykliske acylaminothiazolderivater, deres fremstilling samt farmaceutiske midler indeholdende dem
DK654589D0 (da) Heterocykliske derivater, fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende derivaterne
DK316189D0 (da) Heteroaryloxy-n-isopropylanilider, fremgangsmaade til deres fremstilling samt deres anvendelse
DK25992A (da) Quinolinderivater, deres fremstilling samt farmaeutisk praeparat indeholdende saadanne derivater
DK85087A (da) Substituerede thienoimidazol-derivater, deres fremstilling, praeparater, indeholdende disse, samt anvendelse deraf
EP0429341A3 (en) Heterocyclic derivatives, their preparation and pharmaceuticals containing them
NO942910L (no) Nye baccatin-III- og 10-desacetyl-baccatin-III-derivater, deres fremstillinger, samt farmasöytiske preparater inneholdende derivatene
DK673988A (da) Manumycinderivater, fremgangsaader til deres fremstilling samt deres anvendelse
DK303688A (da) Polyoxygenerede labdanderivater, fremgangsmaade til deres fremstilling samt deres anvendelse som laegemidler
DK165985C (da) 1-cytosinderivater, fremgangsmaader til deres fremstilling, samt anvendelse af dem i og til fremstilling af laegemidler
DK393788A (da) Substituerede thienoimidazolderivater, fremgangsmaader til deres fremstilling samt deres anvendelse som laegemidler
DK114189D0 (da) Benzocycloheptenderivater, samt laegemidler med indhold af saadanne forbindelser
DK178589A (da) Triazoloaziner, fremgangsmaade til deres fremstilling samt deres anvendelse
DK552989A (da) Thiazolderivater, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende dem
DK157389D0 (da) Fluorphosphonatnucleotidderivater samt fremstilling heraf
DK378989A (da) Halogenvinylazolderivater, fremgangsmaader til deres fremstilling samt deres anvendelse
DK630788A (da) N-substituerede dichlormaleinimider, fremgangsmaade til deres fremstiling samt deres anvendelse
DK259089D0 (da) Aminoguanidinoaziner, fremgangsmaade til deres fremstilling samt deres anvendelse
DK62889D0 (da) 1-aminomethyl-3-(2-flour-3-chlorphenyl)-4-cyanopyrrolderivater, fremgangsmaader til deres fremstilling samt deres anvendelse
DK208689A (da) 3-cyano-4-phenyl-pyrrolderivater, fremgangsmaade til deres fremstilling samt deres anvendelse
DK447687D0 (da) Urdamycin g og derivater deraf samt deres fremstilling og anvendelse
FI932332A7 (fi) Uudet pyridobentsoindolijohdannaiset, niiden valmistus ja niitä sisält ävät farmaseuttiset valmisteet
NO950722D0 (no) Ureido-acetamidderivater, deres fremstilling samt medikamenter inneholdende derivatene
NO931765L (no) Pyridobenzoindol-derivater, deres fremstilling samt farmasoeytiske preparater inneholdende forbindelsen
DK222089A (da) 4-aza-1,10-phenanthrolinderivater, fremgangsmaader til deres fremstilling samt deres anvendelse